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1 ANEXOS 
 
 
 
 
 
 
 
 
 
 
 
1.1 Norma EU GMPAnnex 11 
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EUROPEAN COMMISSION  
HEALTH AND CONSUMERS DIRECTORATE-GENERAL 
Public Health and Risk Assessment  
Pharmaceuticals  
 
Brussels, 
SANCO/C8/AM/sl/ares(2010)1064599 
 
EudraLex 
The Rules Governing Medicinal Products in the European Union  
 
Volume 4 
Good Manufacturing Practice Medicinal Products for Human and Veterinary 
Use  
 
 
Annex 11: Computerised Systems  
Legal basis for publishing the detailed guidelines: Article 47 of Directive 
2001/83/EC on the Community code relating to medicinal products for human use 
and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary 
medicinal products. This document provides guidance for the interpretation of the 
principles and guidelines of good manufacturing practice (GMP) for medicinal 
products as laid down in Directive 2003/94/EC for medicinal products for human use 
and Directive 91/412/EEC for veterinary use.  
 
 
Status of the document: revision 1  
Reasons for changes: the Annex has been revised in response to the increased 
use of computerised systems and the increased complexity of these systems. 
Consequential amendments are also proposed for Chapter 4 of the GMP Guide.  
Deadline for coming into operation: 30 June 2011  
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Commission Européenne, B-1049 Bruxelles / 
EuropeseCommissie, B-1049 Brussel - Belgium 
Telephone: (32-2) 299 11 11  
Principle  
This annex applies to all forms of computerised systems used as part of a GMP 
regulated activities. A computerised system is a set of software and hardware 
components which together fulfill certain functionalities.  
The application should be validated; IT infrastructure should be qualified.   
Where a computerised system replaces a manual operation, there should be no 
resultant decrease in product quality, process control or quality assurance. There 
should be no increase in the overall risk of the process.  
 
General  
1. Risk Management  
Risk management should be applied throughout the lifecycle of the computerised 
system taking into account patient safety, data integrity and product quality. As part 
of a risk management system, decisions on the extent of validation and data integrity 
controls should be based on a justified and documented risk assessment of the 
computerised system.   
2. Personnel  
There should be close cooperation between all relevant personnel such as Process 
Owner, System Owner, Qualified Persons and IT. All personnel should have 
appropriate qualifications, level of access and defined responsibilities to carry out 
their assigned duties.   
3. Suppliers and Service Providers  
3.1 When third parties (e.g. suppliers, service providers) are used e.g. to provide, 
install, configure, integrate, validate, maintain (e.g. via remote access), modify or 
retain a computerised system or related service or for data processing, formal 
agreements must exist between the manufacturer and any third parties, and these 
agreements should include clear statements of the responsibilities of the third party. 
IT-departments should be considered analogous.  
3.2 The competence and reliability of a supplier are key factors when selecting a 
product or service provider. The need for an audit should be based on a risk 
assessment.   
3.3 Documentation supplied with commercial off-the-shelf products should be 
reviewed by regulated users to check that user requirements are fulfilled.   
3.4 Quality system and audit information relating to suppliers or developers of 
software and implemented systems should be made available to inspectors on request. 
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Project Phase  
4. Validation  
4.1 The validation documentation and reports should cover the relevant steps of the 
life cycle. Manufacturers should be able to justify their standards, protocols, 
acceptance criteria, procedures and records based on their risk assessment.  
 
4.2 Validation documentation should include change control records (if applicable) 
and reports on any deviations observed during the validation process. 
 
4.3 An up to date listing of all relevant systems and their GMP functionality 
(inventory) should be available. For critical systems an up to date system description 
detailing the physical and logical arrangements, data flows and interfaces with other 
systems or processes, any hardware and software pre-requisites, and security 
measures should be available.   
4.4 User Requirements Specifications should describe the required functions of the 
computerised system and be based on documented risk assessment and GMP impact. 
User requirements should be traceable throughout the life-cycle.  
4.5 The regulated user should take all reasonable steps, to ensure that the system has 
been developed in accordance with an appropriate quality management system. The 
supplier should be assessed appropriately.  
4.6 For the validation of bespoke or customisedcomputerised systems there should 
be a process in place that ensures the formal assessment and reporting of quality and 
performance measures for all the life-cycle stages of the system.   
4.7 Evidence of appropriate test methods and test scenarios should be demonstrated. 
Particularly, system (process) parameter limits, data limits and error handling should 
be considered. Automated testing tools and test environments should have 
documented assessments for their adequacy.   
4.8 If data are transferred to another data format or system, validation should include 
checks that data are not altered in value and/or meaning during this migration process.  
Operational Phase  
5. Data  
Computerised systems exchanging data electronically with other systems should 
include appropriate built-in checks for the correct and secure entry and processing of 
data, in order to minimize the risks.   
6. Accuracy Checks  
For critical data entered manually, there should be an additional check on the 
accuracy of the data. This check may be done by a second operator or by validated 
electronic means. The criticality and the potential consequences of erroneous or 
incorrectly entered data to a system should be covered by risk management. 
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7. Data Storage  
7.1 Data should be secured by both physical and electronic means against damage. 
Stored data should be checked for accessibility, readability and accuracy. Access to 
data should be ensured throughout the retention period.  
7.2 Regular back-ups of all relevant data should be done. Integrity and accuracy of 
backup data and the ability to restore the data should be checked during validation 
and monitored periodically.  
 
8. Printouts  
 
8.1 It should be possible to obtain clear printed copies of electronically stored data.   
 
8.2 For records supporting batch release it should be possible to generate printouts 
indicating if any of the data has been changed since the original entry.  
9. Audit Trails  
 
Consideration should be given, based on a risk assessment, to building into the 
system the creation of a record of all GMP-relevant changes and deletions (a system 
generated "audit trail"). For change or deletion of GMP-relevant data the reason 
should be documented. Audit trails need to be available and convertible to a generally 
intelligible form and regularly reviewed.  
10. Change and Configuration Management  
Any changes to a computerised system including system configurations should only 
be made in a controlled manner in accordance with a defined procedure.   
11. Periodic evaluation  
Computerised systems should be periodically evaluated to confirm that they remain in 
a valid state and are compliant with GMP. Such evaluations should include, where 
appropriate, the current range of functionality, deviation records, incidents, problems, 
upgrade history, performance, reliability, security and validation status reports.  
12. Security  
12.1 Physical and/or logical controls should be in place to restrict access to 
computerised system to authorised persons. Suitable methods of preventing 
unauthorised entry to the system may include the use of keys, pass cards, personal 
codes with passwords, biometrics, restricted access to computer equipment and data 
storage areas.   
12.2 The extent of security controls depends on the criticality of the computerised 
system.   
12.3 Creation, change, and cancellation of access authorisations should be recorded.   
12.4 Management systems for data and for documents should be designed to record 
ESTUDIO DISEÑO GMAO EN SECTOR FARMACÉUTICO  FRANCESC DELGADO 
 
10 
 
the identity of operators entering, changing, confirming or deleting data including 
date and time.  
13. Incident Management  
All incidents, not only system failures and data errors, should be reported and 
assessed. The root cause of a critical incident should be identified and should form 
the basis of corrective and preventive actions. 
14. Electronic Signature  
Electronic records may be signed electronically. Electronic signatures are expected 
to:   
a. have the same impact as hand-written signatures within the boundaries of the 
company,   
b. be permanently linked to their respective record,   
c. include the time and date that they were applied.   
 
15. Batch release  
When a computerised system is used for recording certification and batch release, the 
system should allow only Qualified Persons to certify the release of the batches and it 
should clearly identify and record the person releasing or certifying the batches. This 
should be performed using an electronic signature.  
16. Business Continuity  
For the availability of computerised systems supporting critical processes, provisions 
should be made to ensure continuity of support for those processes in the event of a 
system breakdown (e.g. a manual or alternative system).  The time required to bring 
the alternative arrangements into use should be based on risk and appropriate for a 
particular system and the business process it supports. These arrangements should be 
adequately documented and tested.   
17. Archiving  
Data may be archived. This data should be checked for accessibility, readability and 
integrity. If relevant changes are to be made to the system (e.g. computer equipment 
or programs), then the ability to retrieve the data should be ensured and tested. 
 
Glossary  
Application: Software installed on a defined platform/hardware providing specific 
functionality  
Bespoke/Customized computerised system: A computerised system individually 
designed to suit a specific business process   
Commercial of the shelf software: Software commercially available, whose fitness 
for use is demonstrated by a broad spectrum of users.    
IT Infrastructure: The hardware and software such as networking software and 
operation systems, which makes it possible for the application to function.   
FRANCESCDELGADO ESTUDIO DISEÑO GMAO EN SECTOR FARMACÉUTICO 
 
11 
 
Life cycle: All phases in the life of the system from initial requirements until 
retirement including design, specification, programming, testing, installation, 
operation, and maintenance.   
Process owner: The person responsible for the business process.  
System owner: The person responsible for the availability, and maintenance of a 
computerised system and for the security of the data residing on that system.   
Third Party: Parties not directly managed by the holder of the manufacturing and/or 
import authorisation. 
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U.S. Food & Drug Administration  


CFR - Code of Federal Regulations Title 21  
 
 
[Code of Federal Regulations][Title 21, Volume 1][Revised 
as of April 1, 2011][CITE: 21CFR11]  
 
TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG 
ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES  
 
SUBCHAPTER A--GENERAL PART 11 ELECTRONIC RECORDS; ELECTRONIC 
SIGNATURES  
 
 
Subpart A--General Provisions  
Sec. 11.1 Scope. 
(a) The regulations in this part set forth the criteria 
under which the agency considers electronic records, 
electronic signatures, and handwritten signatures executed 
to electronic records to be trustworthy, reliable, and 
generally equivalent to paper records and handwritten 
signatures executed on paper.  
(b) This part applies to records in electronic form that are 
created, modified, maintained, archived, retrieved, or 
transmitted, under any records requirements set forth in 
agency regulations. This part also applies to electronic 
records submitted to the agency under requirements of the 
Federal Food, Drug, and Cosmetic Act and the Public Health 
Service Act, even if such records are not specifically 
identified in agency regulations. However, this part does 
not apply to paper records that are, or have been, 
transmitted by electronic means.  
(c) Where electronic signatures and their associated 
electronic records meet the requirements of this part, the 
agency will consider the electronic signatures to be 
equivalent to full handwritten signatures, initials, and 
other general signings as required by agency regulations, 
unless specifically excepted by regulation(s) effective on 
or after August 20, 1997.  
(d) Electronic records that meet the requirements of this 
part may be used in lieu of paper records, in accordance 
with 11.2, unless paper records are specifically required.  
(e) Computer systems (including hardware and software), 
controls, and attendant documentation maintained under this 
part shall be readily available for, and subject to, FDA 
inspection.  
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(f) This part does not apply to records required to be 
established or maintained by 1.326 through 1.368 of this 
chapter. Records that satisfy the requirements of part 1, 
subpart J of this chapter, but that also are required under 
other applicable statutory provisions or regulations, remain 
subject to this part.  
 
[62 FR 13464, Mar. 20, 1997, as amended at 69 FR 71655, 
Dec. 9, 2004]   
Sec. 11.2 Implementation. 
(a) For records required to be maintained but not submitted 
to the agency, persons may use electronic records in lieu of 
paper records or electronic signatures in lieu of 
traditional signatures, in whole or in part, provided that 
the requirements of this part are met.  
(b) For records submitted to the agency, persons may use 
electronic records in lieu of paper records or electronic 
signatures in lieu of traditional signatures, in whole or in 
part, provided that:  
(1) The requirements of this part are met; and  
(2) The document or parts of a document to be submitted have 
been identified in public docket No. 92S-0251 as being the 
type of submission the agency accepts in electronic form. 
This docket will identify specifically what types of 
documents or parts of documents are acceptable for 
submission in electronic form without paper records and the 
agency receiving unit(s) (e.g., specific center, office, 
division, branch) to which such submissions may be made. 
Documents to agency receiving unit(s) not specified in the 
public docket will not be considered as official if they are 
submitted in electronic form; paperforms of such documents 
will be considered as official and must accompany any 
electronic records. Persons are expected to consult with the 
intended agency receiving unit for details on how (e.g., 
method of transmission, media, file formats, and technical 
protocols) and whether to proceed with the electronic 
submission. 
 
Sec. 11.3 Definitions. 
(a) The definitions and interpretations of terms contained 
in section 201 of the act apply to those terms when used in 
this part.  
(b) The following definitions of terms also apply to this 
part:  
 
(1)Act means the Federal Food, Drug, and Cosmetic Act 
(secs. 201-903 (21  
U.S.C. 321-393)).  
(2)Agency means the Food and Drug Administration.  
(3)Biometrics means a method of verifying an individual's 
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identity based on measurement of the individual's physical 
feature(s) or repeatable action(s) where those features 
and/or actions are both unique to that individual and 
measurable.  
(4)Closed system means an environment in which system 
access is controlled by persons who are responsible for 
the content of electronic records that are on the system.  
(5)Digital signature means an electronic signature based 
upon cryptographic methods of originator authentication, 
computed by using a set of rules and a set of parameters 
such that the identity of the signer and the integrity of 
the data can be verified.  
(6)Electronic record means any combination of text, 
graphics, data, audio, pictorial, or other information 
representation in digital form that is created, modified, 
maintained, archived, retrieved, or distributed by a 
computer system.  
(7)Electronic signature means a computer data compilation 
of any symbol or series of symbols executed, adopted, or 
authorized by an individual to be the legally binding 
equivalent of the individual's handwritten signature.  
(8)Handwritten signature means the scripted name or legal 
mark of anindividual handwritten by that individual and 
executed or adopted with the present intention to 
authenticate a writing in a permanent form. The act of 
signing with a writing or marking instrument such as a pen 
or stylus is preserved. The scripted name or legal mark, 
while conventionally applied to paper, may also be applied 
to other devices that capture the name or mark.  
(9)Open system means an environment in which system access 
is not controlled by persons who are responsible for the 
content of electronic records that are on the system.  
Subpart B--Electronic Records  
Sec. 11.10 Controls for closed systems.  
Persons who use closed systems to create, modify, 
maintain, or transmit electronic records shall employ 
procedures and controls designed to ensure the 
authenticity, integrity, and, when appropriate, the 
confidentiality of electronic records, and to ensure that 
the signer cannot readily repudiate the signed record as 
not genuine. Such procedures and controls shall include 
the following:  
(a) Validation of systems to ensure accuracy, reliability, 
consistent intended performance, and the ability to discern 
invalid or altered records.  
(b) The ability to generate accurate and complete copies of 
records in both human readable and electronic form suitable 
for inspection, review, and copying by the agency. Persons 
should contact the agency if there are any questions 
regarding the ability of the agency to perform such review 
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and copying of the electronic records.  
(c) Protection of records to enable their accurate and ready 
retrieval throughout the records retention period.  
(d) Limiting system access to authorized individuals.  
(e) Use of secure, computer-generated, time-stamped audit 
trails to independently record the date and time of operator 
entries and actions that create, modify, or delete 
electronic records. Record changes shall not obscure 
previously recorded information. Such audit trail 
documentation shall be retained for a period at least as 
long as that required for the subject electronic records and 
shall be available for agency review and copying.  
(f) Use of operational system checks to enforce permitted 
sequencing of steps and events, as appropriate.  
(g) Use of authority checks to ensure that only authorized 
individuals can use the system, electronically sign a 
record, access the operation or computer system input or 
output device, alter a record, or perform the operation at 
hand.  
(h) Use of device (e.g., terminal) checks to determine, as 
appropriate, the validity of the source of data input or 
operational instruction.  
(i) Determination that persons who develop, maintain, or use 
electronic record/electronic signature systems have the 
education, training, and experience to perform their 
assigned tasks.  
(j) The establishment of, and adherence to, written policies 
that hold individuals accountable and responsible for 
actions initiated under their electronic signatures, in 
order to deter record and signature falsification.  
(k) Use of appropriate controls over systems documentation 
including:  
(1) Adequate controls over the distribution of, access to, 
and use of documentation for system operation and 
maintenance.  
(2) Revision and change control procedures to maintain an 
audit trail that documents time-sequenced development and 
modification of systems documentation.  
 
Sec. 11.30 Controls for open systems.  
Persons who use open systems to create, modify, maintain, 
or transmit electronic records shall employ procedures and 
controls designed to ensure the authenticity, integrity, 
and, as appropriate, the confidentiality of electronic 
records from the point of their creation to the point of 
their receipt. Such procedures and controls shall include 
those identified in 11.10, as appropriate, and additional 
measures such as document encryption and use of appropriate 
digital signature standards to ensure, as necessary under 
the circumstances, record authenticity, integrity, and 
confidentiality.  
Sec. 11.50 Signature manifestations. 
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(a) Signed electronic records shall contain information 
associated with the signing that clearly indicates all of 
the following:  
(1) The printed name of the signer;  
(2) The date and time when the signature was executed; and  
(3) The meaning (such as review, approval, responsibility, 
or authorship) associated with the signature.  
(b) The items identified in paragraphs (a)(1), (a)(2), and 
(a)(3) of this section shall be subject to the same controls 
as for electronic records and shall be included as part of 
any human readable form of the electronic record (such as 
electronic display or printout).  
 
Sec. 11.70 Signature/record linking. 
Electronic signatures and handwritten signatures executed 
to electronic records shall be linked to their respective 
electronic records to ensure that the signatures cannot be 
excised, copied, or otherwise transferred to falsify an 
electronic record by ordinary means. 
 
 
Subpart C--Electronic Signatures  
Sec. 11.100 General requirements. 
(a) Each electronic signature shall be unique to one 
individual and shall not be reused by, or reassigned to, 
anyone else.  
(b) Before an organization establishes, assigns, certifies, 
or otherwise sanctions an individual`s electronic signature, 
or any element of such electronic signature, the 
organization shall verify the identity of the individual.  
(c) Persons using electronic signatures shall, prior to or 
at the time of such use, certify to the agency that the 
electronic signatures in their system, used on or after 
August 20, 1997, are intended to be the legally binding 
equivalent of traditional handwritten signatures.  
(1) The certification shall be submitted in paper form and 
signed with a traditional handwritten signature, to the 
Office of Regional Operations (HFC-100), 12420 Parklawn 
Drive, RM 3007 Rockville, MD 20857.  
(2) Persons using electronic signatures shall, upon agency 
request, provide additional certification or testimony that 
a specific electronic signature is the legally binding 
equivalent of the signer`s handwritten signature. Sec. 
11.200 Electronic signature components and controls. 
(a) Electronic signatures that are not based upon biometrics 
shall:  
(1) Employ at least two distinct identification components 
such as an identification code and password.  
(i) When an individual executes a series of signings during 
a single, continuous period of controlled system access, the 
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first signing shall be executed using all electronic 
signature components; subsequent signings shall be executed 
using at least one electronic signature component that is 
only executable by, and designed to be used only by, the 
individual.  
(ii) When an individual executes one or more signings not 
performed during a single, continuous period of controlled 
system access, each signing shall be executed using all of 
the electronic signature components.  
(2) Be used only by their genuine owners; and  
(3) Be administered and executed to ensure that attempted 
use of an individual's electronic signature by anyone other 
than its genuine owner requires collaboration of two or more 
individuals.  
(b) Electronic signatures based upon biometrics shall be 
designed to ensure that they cannot be used by anyone other 
than their genuine owners.  
 
Sec. 11.300 Controls for identification codes/passwords.  
Persons who use electronic signatures based upon use of 
identification codes in combination with passwords shall 
employ controls to ensure their security and integrity. 
Such controls shall include:  
(a) Maintaining the uniqueness of each combined 
identification code and password, such that no two 
individuals have the same combination of identification code 
and password.  
(b) Ensuring that identification code and password issuances 
are periodically checked, recalled, or revised (e.g., to 
cover such events as password aging).  
(c) Following loss management procedures to electronically 
deauthorize, lost, stolen, missing, or otherwise potentially 
compromised tokens, cards, and other devices that bear or 
generate identification code or password information, and to 
issue temporary or permanent replacements using suitable, 
rigorous controls.  
(d) Use of transaction safeguards to prevent unauthorized 
use of passwords and/or identification codes, and to detect 
and report in an immediate and urgent manner any attempts at 
their unauthorized use to the system security unit, and, as 
appropriate, to organizational management.  
(e) Initial and periodic testing of devices, such as tokens 
or cards, that bear or generate identification code or 
password information to ensure that they function properly 
and have not been altered in an unauthorized manner.  
 
Authority: 21 U.S.C. 321-393; 42 U.S.C. 262.  
Source: 62 FR 13464, Mar. 20, 1997, unless otherwise noted.   
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